drugset / Trial / NCT03747523

Pilot Study: The Effect of Ergocalciferol on Plasma Mucin-1 Levels

NCT03747523

Phase 0 Completed 44 enrolled Wake Forest University Health Sciences
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To determine if a one-time oral administration of ergocalciferol results in a decline in plasma mucin-1 levels in healthy individuals and individuals with ADTKD-MUC1.

Timeline

Start
2019-03-12
Primary completion
2019-12-20
Completion
2020-01-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ergocalciferol Small molecule 200000 iu Oral

Indications

No indication recorded.